Oxcarbazepine and Hepatocellular injury - a phase IV clinical study of FDA data

Summary:

Hepatocellular injury is found among people who take Oxcarbazepine, especially for people who are female, 50-59 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Oxcarbazepine and have Hepatocellular injury. It is created by eHealthMe based on reports of 10,768 people who have side effects when taking Oxcarbazepine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Jun, 14, 2022

10,768 people reported to have side effects when taking Oxcarbazepine.
Among them, 14 people (0.13%) have Hepatocellular injury.


What is Oxcarbazepine?

Oxcarbazepine has active ingredients of oxcarbazepine. It is often used in epilepsy. eHealthMe is studying from 11,198 Oxcarbazepine users for its effectiveness, alternative drugs and more.

What is Hepatocellular injury?

Hepatocellular injury (liver injury) is found to be associated with 958 drugs and 882 conditions by eHealthMe.

Number of Oxcarbazepine and Hepatocellular injury reports submitted per year:

Could Oxcarbazepine cause Hepatocellular injury?

Time on Oxcarbazepine when people have Hepatocellular injury *:

  • < 1 month: 66.67 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 33.33 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Hepatocellular injury when taking Oxcarbazepine *:

  • female: 76.92 %
  • male: 23.08 %

Age of people who have Hepatocellular injury when taking Oxcarbazepine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 7.69 %
  • 50-59: 84.62 %
  • 60+: 7.69 %

Common drugs people take besides Oxcarbazepine *:

  1. Paracetamol: 10 people, 71.43%
  2. Zemuron: 1 person, 7.14%
  3. Vitamin E: 1 person, 7.14%
  4. Versed: 1 person, 7.14%
  5. Trileptal: 1 person, 7.14%
  6. Sevoflurane: 1 person, 7.14%
  7. Saw Palmetto: 1 person, 7.14%
  8. Ginseng: 1 person, 7.14%
  9. Fentanyl: 1 person, 7.14%
  10. Cefazolin: 1 person, 7.14%

Common side effects people have besides Hepatocellular injury *:

  1. Fatigue (feeling of tiredness): 6 people, 42.86%
  2. Abdominal Pain Upper: 6 people, 42.86%
  3. Nausea And Vomiting: 1 person, 7.14%
  4. Nausea (feeling of having an urge to vomit): 1 person, 7.14%
  5. Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 1 person, 7.14%
  6. Itching: 1 person, 7.14%
  7. Headache (pain in head): 1 person, 7.14%
  8. Gallbladder Disorder: 1 person, 7.14%
  9. Faeces Discolored: 1 person, 7.14%
  10. Drug-Induced Liver Injury (diseases of the liver that are caused by physician-prescribed medications): 1 person, 7.14%

Common conditions people have *:

  1. Depression: 8 people, 57.14%
  2. Pain: 2 people, 14.29%
  3. Viral Infection: 1 person, 7.14%
  4. Lipids Abnormal: 1 person, 7.14%
  5. Bleeding Disorders: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Oxcarbazepine and have Hepatocellular injury?

Check whether Hepatocellular injury is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Hepatocellular injury and when was it recovered:

Expand to all the drugs that have ingredients of oxcarbazepine:

Alternative drugs to, pros and cons of Oxcarbazepine:

Common Oxcarbazepine side effects:

Browse all side effects of Oxcarbazepine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hepatocellular injury treatments and more:

COVID vaccines that are related to Hepatocellular injury:

Common drugs associated with Hepatocellular injury:

All the drugs that are associated with Hepatocellular injury:

Common conditions associated with Hepatocellular injury:

All the conditions that are associated with Hepatocellular injury:

How the study uses the data?

The study uses data from the FDA. It is based on oxcarbazepine (the active ingredients of Oxcarbazepine) and Oxcarbazepine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: